Dapoxetine Hydrochloride
Dapoxetine Hydrochloride structure
|
Common Name | Dapoxetine Hydrochloride | ||
|---|---|---|---|---|
| CAS Number | 129938-20-1 | Molecular Weight | 341.874 | |
| Density | N/A | Boiling Point | 454.4ºC at 760 mmHg | |
| Molecular Formula | C21H24ClNO | Melting Point | 175-179ºC | |
| MSDS | Chinese USA | Flash Point | 132.6ºC | |
| Symbol |
GHS07 |
Signal Word | Warning | |
|
New insights on premature ejaculation: a review of definition, classification, prevalence and treatment.
Asian J. Androl. 14(6) , 822-9, (2012) There are ongoing debates about the definition, classification and prevalence of premature ejaculation (PE). The first evidence-based definition of PE was limited to heterosexual men with lifelong PE who engage in vaginal intercourse. Unfortunately, many pati... |
|
|
Chiral recognition of dapoxetine enantiomers with methylated-gamma-cyclodextrin: a validated capillary electrophoresis method.
J. Pharm. Biomed. Anal. 62 , 42-7, (2012) The enantiomers of dapoxetine, a serotonin transporter inhibitor for the treatment of premature ejaculation have been separated by cyclodextrin modified capillary zone electrophoresis using uncoated fused-silica capillary. Over 20 cyclodextrins were screened ... |
|
|
Dapoxetine for premature ejaculation.
Expert Opin. Pharmacother. 11(10) , 1741-52, (2010) Premature ejaculation (PE) is a common male sexual disorder which is associated with substantial personal and interpersonal negative psychological factors. Drug treatment of PE with an off-label antidepressant selective serotonin reuptake inhibitor (SSRI) dru... |
|
|
Oral agents for the treatment of premature ejaculation: review of efficacy and safety in the context of the recent International Society for Sexual Medicine criteria for lifelong premature ejaculation.
J. Sex. Med. 8(10) , 2707-25, (2011) New diagnostic criteria for lifelong premature ejaculation (PE) have been proposed by the International Society of Sexual Medicine (ISSM), including an intravaginal ejaculatory latency time (IELT) of less than about 1 minute, lack of control over ejaculation,... |
|
|
Effect of dapoxetine on ejaculatory performance and related brain neuronal activity in rapid ejaculator rats.
J. Sex. Med. 9(10) , 2562-73, (2012) A brain network specifically activated when ejaculation occurs has been described in rats. Increasing serotonin (5-hydroxytryptamine [5-HT]) tone impairs ejaculation and chronic 5-HT selective serotonin reuptake inhibitors (SSRIs) are known to inhibit ejacula... |
|
|
A benefit-risk assessment of dapoxetine in the treatment of premature ejaculation.
Drug Saf. 35(5) , 359-72, (2012) Premature ejaculation (PE) is considered to be the most common sexual problem affecting men, despite the likelihood that it is under-diagnosed. It is a complex condition with many physical and psychological components, making management complicated. It is imp... |
|
|
Determination of dapoxetine in rat plasma by ultra-performance liquid chromatography-tandem mass spectrometry.
J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 926 , 42-6, (2013) In this study, we describe and validate a rapid and sensitive method for quantitation of dapoxetine in rat plasma by using ultra-performance liquid chromatography-electrospray ionization tandem mass spectrometry (UPLC-ESI/MS/MS). Plasma samples were prepared ... |
|
|
Effects of dapoxetine on cloned Kv1.5 channels expressed in CHO cells.
Naunyn Schmiedebergs Arch. Pharmacol. 385(7) , 707-16, (2012) The effects of dapoxetine were examined on cloned Kv1.5 channels stably expressed in Chinese hamster ovary cells using the whole-cell patch clamp technique. Dapoxetine decreased the peak amplitude of Kv1.5 currents and accelerated the decay rate of current in... |
|
|
Available and future therapies for premature ejaculation.
Drugs Today (Barc) 46(7) , 507-21, (2010) Premature ejaculation (PE), the most common male sexual dysfunction, impacts the quality of life of not only the affected male but also his partner. Despite its prevalence, there are currently no United States Food and Drug Administration-approved therapies f... |
|
|
Patient reporting encouraged during monitoring of dapoxetine in New Zealand.
Drug Saf. 34(11) , 1115-6, (2011)
|